Literature DB >> 22412045

HER2 expression in ovarian carcinoma: caution and complexity in biomarker analysis.

Hugh McCaughan, Inhwa Um, Simon P Langdon, David J Harrison, Dana Faratian.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22412045     DOI： 10.1136/jclinpath-2011-200616

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


× No keyword cloud information.
  6 in total

Review 1.  HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies.

Authors:  Diana P English; Dana M Roque; Alessandro D Santin
Journal:  Mol Diagn Ther       Date:  2013-04       Impact factor: 4.074

2.  Overexpression of β-catenin and cyclinD1 predicts a poor prognosis in ovarian serous carcinomas.

Authors:  Hai Wang; Haiyan Wang; Mohammad Shahidul Makki; Juanjuan Wen; Yingqing Dai; Qunli Shi; Qi Liu; Xiaojun Zhou; Jiandong Wang
Journal:  Int J Clin Exp Pathol       Date:  2013-12-15

3.  HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer.

Authors:  Wen-Yee Chay; Sung-Hock Chew; Whee-Sze Ong; Inny Busmanis; Xinyun Li; Sharyl Thung; Lynette Ngo; Sheow-Lei Lim; Yong-Kuei Lim; Yin-Nin Chia; Elisa Koh; Cindy Pang; Lay-Tin Soh; Jin Wang; Tew-Hong Ho; Sun-Kuie Tay; Soo-Kim Lim-Tan; Kiat-Hon Lim; John Whay-Kuang Chia; Liang-Kee Goh
Journal:  PLoS One       Date:  2013-04-19       Impact factor: 3.240

4.  A qualitative study comparing the assay performance characteristics between the 2007 and the 2013 American Society for Clinical Oncology and College of American Pathologists HER2 scoring methods in mucinous epithelial ovarian cancer.

Authors:  Chi-Kuan Chen; Ming-Yung Lee; Wea-Lung Lin; Yu-Ting Wang; Chih-Ping Han; Cheng-Ping Yu; Wan-Ru Chao
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

5.  Assessment of HER2 Status Using Immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) Techniques in Mucinous Epithelial Ovarian Cancer: A Comprehensive Comparison between ToGA Biopsy Method and ToGA Surgical Specimen Method.

Authors:  Wan-Ru Chao; Ming-Yung Lee; Alexandra Ruan; Huang Pin Sheng; Jeng-Dong Hsu; Chih-Ping Han; Chiew-Loon Koo
Journal:  PLoS One       Date:  2015-11-13       Impact factor: 3.240

6.  Correlation between HER-2/neu(erbB-2) expression level and therapeutic effect of combination treatment with HERCEPTIN and chemotherapeutic agents in gastric cancer cell lines.

Authors:  Hai Cui; Ying Cheng; Su-Zhou Piao; Yun-Jie Xu; Hong-Hua Sun; Xian Cui; Xiang-Zi Li; Song-Nan Zhang; Long-Zhen Piao; Yong-Min Jin; Zhen-Hua Lin; Xiong-Hu Shen
Journal:  Cancer Cell Int       Date:  2014-01-29       Impact factor: 5.722
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.